ARDELYX, INC. Increase (Decrease) in Inventories
ARDELYX, INC. (ARDX) reported Increase (Decrease) in Inventories of $15.88 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- ARDELYX, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $10.96M, a 36.95% decline year-over-year.
- ARDELYX, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $4.92M, a 66.53% decline year-over-year.
- ARDELYX, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$6.25M, a 203.73% decline year-over-year.
- ARDELYX, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $6.10M, a 253.36% increase year-over-year.
- ARDELYX, INC. increase (decrease) in inventories for fiscal 2025 was $31.92M, a 23.44% decline from fiscal 2024.
- ARDELYX, INC. increase (decrease) in inventories for fiscal 2024 was $41.70M, a 97.23% increase from fiscal 2023.
- ARDELYX, INC. increase (decrease) in inventories for fiscal 2023 was $21.14M, a 25.42% decline from fiscal 2022.
- ARDELYX, INC. increase (decrease) in inventories for fiscal 2022 was $28.35M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.88M 10-Q · filed 2026-08-06 | $9.63M derived: sum of 3 quarters · filed 2026-08-06 | $15.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.92M 10-Q · filed 2026-04-30 | -$1.33M derived: sum of 2 quarters · filed 2026-04-30 | $4.77M derived: sum of 3 quarters · filed 2026-04-30 | $22.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$152.00K derived: sum of 2 quarters · filed 2026-02-19 | $17.23M derived: sum of 3 quarters · filed 2026-08-06 | $31.92M 10-K · filed 2026-02-19 |
| 2025-09-30 | $6.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $23.48M derived: sum of 2 quarters · filed 2026-08-06 | $38.17M 10-Q · filed 2025-10-30 | $44.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.08M 10-Q · filed 2026-08-06 | $38.10M derived: sum of 3 quarters · filed 2026-08-06 | $39.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.69M 10-Q · filed 2026-04-30 | $20.72M derived: sum of 2 quarters · filed 2026-04-30 | $22.44M derived: sum of 3 quarters · filed 2026-04-30 | $27.02M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.75M derived: sum of 2 quarters · filed 2026-02-19 | $12.33M derived: sum of 3 quarters · filed 2026-02-19 | $41.70M 10-K · filed 2026-02-19 |
| 2024-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $6.30M derived: sum of 2 quarters · filed 2025-10-30 | $35.67M 10-Q · filed 2025-10-30 | $37.66M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $33.95M 10-Q · filed 2025-08-04 | $35.93M derived: sum of 3 quarters · filed 2026-02-19 | $35.52M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $29.37M 10-Q · filed 2025-05-01 | $31.36M derived: sum of 2 quarters · filed 2026-02-19 | $30.95M derived: sum of 3 quarters · filed 2026-02-19 | $33.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.57M derived: sum of 2 quarters · filed 2026-02-19 | $4.54M derived: sum of 3 quarters · filed 2026-02-19 | $21.14M 10-K · filed 2026-02-19 |
| 2023-09-30 | -$414.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.55M derived: sum of 2 quarters · filed 2024-10-31 | $19.15M 10-Q · filed 2024-10-31 | $37.72M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $19.57M 10-Q · filed 2024-08-01 | $38.14M derived: sum of 3 quarters · filed 2025-02-20 | $43.38M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $16.60M 10-Q · filed 2024-05-02 | $35.17M derived: sum of 2 quarters · filed 2025-02-20 | $40.42M derived: sum of 3 quarters · filed 2025-02-20 | $41.46M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $23.82M derived: sum of 2 quarters · filed 2025-02-20 | $24.86M derived: sum of 3 quarters · filed 2025-02-20 | $28.35M 10-K · filed 2025-02-20 |
| 2022-09-30 | $5.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $6.29M derived: sum of 2 quarters · filed 2023-10-31 | $9.77M 10-Q · filed 2023-10-31 | $9.77M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $4.53M 10-Q · filed 2023-08-02 | $4.53M derived: sum of 3 quarters · filed 2024-02-22 | $4.53M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $3.49M 10-Q · filed 2023-05-03 | $3.49M derived: sum of 2 quarters · filed 2024-02-22 | $3.49M derived: sum of 3 quarters · filed 2024-02-22 | $3.49M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |